Collect Product
Product Details
Synonyms
IL-2 R beta & IL-2 R gamma, IL-2RB & IL-2RG
Source
Rhesus macaque IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag (ILG-R5284) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Thr 240 & Leu 23 - Pro 255 (Accession # NP_001244989.1 & Q38JL2-1).
Predicted N-terminus: Ala 27 & Leu 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
Rhesus macaque IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag is produced by co-expression of IL-2RB and IL-2RG, has a calculated MW of 30.1 kDa (IL-2RB) and 34.1 kDa (IL-2RG). Subunit IL-2RB is fused with a polyhistidine tag at the C-terminus and subunit IL-2RG is fused with Twin-Strep tag at the C-terminus. The protein migrates as 35-44 kDa and 55-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a heterodimer.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Rhesus macaque IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Rhesus macaque IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag (Cat. No. ILG-R5284) is more than 90% and the molecular weight of this protein is around 95-125 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human IL-2, premium grade (Cat. No. IL2-H5215) at 5 μg/mL (100 μL/well) can bind Rhesus macaque IL-2 R beta&IL-2 R gamma Heterodimer Protein, His Tag&Twin-Strep Tag (Cat. No. ILG-R5284) with a linear range of 0.02-0.313 μg/mL (QC tested).
Protocol
User Reviews Publish Comment
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Interleukin-2 receptor subunit gamma
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
14 Details
- Highest R&D Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
